title: Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
abstract: Isocitrate dehydrogenase 1 (IDH1) mutations have been discovered to be frequent and highly conserved in secondary glioblastoma multiforme and lower-grade gliomas. Although IDH1 mutations confer a unique genotype that has been associated with a favorable prognosis, the role of the mutated IDH1 enzyme and its metabolites in tumor initiation and maintenance remains unresolved. However, given that IDH1 mutations are homogeneously expressed and are limited solely to tumor tissue, targeting this mutation could potentially yield novel treatment strategies for patients with glioblastoma multiforme.
authors.affiliation: Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
authors.forename: Tiffany R
authors.initials: TR
authors.lastname: Hodges
authors.forename: Bryan D
authors.initials: BD
authors.lastname: Choi
authors.forename: Darell D
authors.initials: DD
authors.lastname: Bigner
authors.forename: Hai
authors.initials: H
authors.lastname: Yan
authors.forename: John H
authors.initials: JH
authors.lastname: Sampson
mesh_terms: D001932:Brain Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000503:physiopathology; D015972:Gene Expression Regulation, Neoplastic; D005820:Genetic Testing; D005838:Genotype; D005909:Glioblastoma / Q000175:diagnosis / Q000235:genetics* / Q000503:physiopathology; D005910:Glioma / Q000175:diagnosis / Q000235:genetics* / Q000503:physiopathology; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics* / Q000502:physiology; D009154:Mutation / Q000235:genetics* / Q000502:physiology; D011379:Prognosis
chemical_list: D007521:Isocitrate Dehydrogenase